RNF145 Inhibitors
RNF145 inhibitors work through a variety of biochemical mechanisms that all converge on the common pathway of ubiquitination, a process crucial for protein turnover and cellular regulation. Inhibition of the proteasome with compounds that bind to its active sites leads to an accumulation of ubiquitinated proteins, which can indirectly affect the function of RNF145 by overwhelming the proteolytic system it relies on. By inhibiting the proteasome, these compounds effectively prevent the degradation of proteins that RNF145 has marked for turnover, thereby reducing the efficacy of RNF145's role in cellular protein homeostasis. This is exemplified by peptide aldehydes and boronic acid derivatives, which interfere with the proteasome's ability to recognize and process ubiquitinated substrates, leading to a backlog that indirectly limits RNF145's function.
Additionally, inhibitors that target the upstream processes of ubiquitination, such as those affecting the neddylation of cullin proteins or the ubiquitin-activating enzyme E1, can indirectly inhibit RNF145 by disrupting the ubiquitin-proteasome pathway. The neddylation process is integral to the function of cullin-RING ubiquitin ligases, to which RNF145 may contribute, and by impeding this process, the overall ubiquitination activity can be reduced. Similarly, by inhibiting the initial steps of ubiquitin activation and conjugation to target proteins, these compounds can decrease the functional activity of RNF145 by preventing the tagging of proteins for degradation. Deubiquitinase inhibitors further balance the ubiquitination equilibrium by preventing the removal of ubiquitin chains, which could indirectly lead to the inhibition of RNF145's activity by stabilizing its substrates against proteasomal degradation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
This peptide aldehyde functions as a proteasome inhibitor, which could lead to the accumulation of ubiquitinated proteins. RNF145, being a ring finger protein, is likely involved in protein ubiquitination; thus, proteasome inhibition could indirectly reduce RNF145's ability to mediate proteasomal degradation by overwhelming the proteolytic system. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
A selective proteasome inhibitor that covalently binds to proteasome active sites, leading to the reduction of protein degradation. By inhibiting the proteasome, the intended effect would be a decrease in RNF145-mediated protein ubiquitination and subsequent degradation. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
This small molecule is a NEDD8-activating enzyme inhibitor that prevents the neddylation of cullin proteins, which could indirectly affect RNF145's function in protein ubuiqitination, as the neddylation is essential for the activation of cullin-RING ligases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A dipeptidyl boronic acid that inhibits the 26S proteasome, leading to the accumulation of ubiquitinated proteins. As RNF145 is implicated in ubiquitination, this compound could indirectly inhibit RNF145's functional role by preventing the degradation of its ubiquitination targets. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
An irreversible proteasome inhibitor that could lead to the accumulation of proteins that would normally be degraded. This accumulation might inhibit RNF145's role in targeting specific proteins for degradation due to proteasome saturation. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
An irreversible inhibitor of the ubiquitin-activating enzyme E1, potentially reducing ubiquitin conjugation to target proteins. This would affect the ubiquitination process in which RNF145 is involved, leading to its functional inhibition. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
An inhibitor of the deubiquitinating enzyme USP14, which can prevent the removal of ubiquitin from protein substrates. By inhibiting deubiquitination, IU1 could indirectly inhibit RNF145 by altering the balance of protein ubiquitination and stabilization. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
An inducer of endoplasmic reticulum stress, which can lead to the inhibition of proteasome activity. This stress may indirectly inhibit RNF145 by disrupting its protein ubiquitination capacity due to a stressed ER environment. | ||||||
PR 619 | 2645-32-1 | sc-476324 sc-476324A sc-476324B | 1 mg 5 mg 25 mg | $77.00 $188.00 $431.00 | 1 | |
A broad-spectrum deubiquitinase inhibitor that can lead to increased levels of ubiquitinated proteins, potentially affecting RNF145's ability to target proteins for degradation through ubiquitination. | ||||||
MLN7243 | 1450833-55-2 | sc-507338 | 5 mg | $340.00 | ||
A ubiquitin-activating enzyme E1 inhibitor that can reduce the ubiquitination of proteins, which might indirectly inhibit RNF145's function in the ubiquitination process. | ||||||